This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia-Hermoso, D. Articles by Dupont, B. Search for Related Content PubMed PubMed Citation Articles by Garcia-Hermoso, D. Articles by Dupont, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 03 1995, 656-660, Vol 39, No. 3
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole

D Garcia-Hermoso, F Dromer, L Improvisi, F Provost and B Dupont
Unite de Mycologie, Institut Pasteur, Paris, France.

Fluconazole (FCZ) has been extensively used as a primary therapy for oropharyngeal candidosis in AIDS patients. Clinical resistance to FCZ is now encountered, often related to decreased susceptibility of the isolate in vitro. We wondered if low levels in saliva play a role in the therapeutic failure, especially in patients complaining of dry mouth. Sixteen AIDS patients treated for oropharyngeal candidosis with FCZ were studied. MICs for the isolates were determined. Serum and saliva samples were collected to measure FCZ levels with a bioassay using paper disks loaded with the clinical specimens. We showed that (i) paper disks were convenient for collecting saliva in patients with dry mouth; (ii) levels in saliva depended on the FCZ dosage regimen but did not correlate with the response to therapy; (iii) correlation between concentrations in saliva and serum was poor and independent of clinical response to treatment, other therapies, or decreased salivation; and (iv) levels in saliva were always lower than MICs in patients who failed to respond to treatment. In conclusion, therapeutic failures are more likely to be related to in vitro resistance of the isolate to FCZ or insufficient dosage regimen than to decreased salivary secretion.

This article has been cited by other articles:

• Walsh, T. J., Gonzalez, C. E., Piscitelli, S., Bacher, J. D., Peter, J., Torres, R., Shetti, D., Katsov, V., Kligys, K., Lyman, C. A. (2000). Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. J. Clin. Microbiol. 38: 2369-2373 [Abstract] [Full Text]  
• Kuipers, M. E., de Vries, H. G., Eikelboom, M. C., Meijer, D. K. F., Swart, P. J. (1999). Synergistic Fungistatic Effects of Lactoferrin in Combination with Antifungal Drugs against Clinical Candida Isolates. Antimicrob. Agents Chemother. 43: 2635-2641 [Abstract] [Full Text]  
• Lortholary, O., Nicolas, M., Soreda, S., Improvisi, L., Ronin, O., Petitjean, O., Dupont, B., Tod, M., Dromer, F. (1999). Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother 43: 817-824 [Abstract] [Full Text]